Summary
The amphetamine analog, 2,5-dimethoxy-4-methylamphetamine (DOM), was studied in 18 volunteer subjects given single doses ranging from 2 to 14 mg. The former was a threshold dose, with definite psychotomimetic effects being evident from doses over 5 mg. The clinical syndrome greatly resembled that of the LSD-mescaline-psilocybin series of drugs, including its time-course. Somewhat more sedation was produced by DOM than would have been expected from the others, despite concomitant evidence of peripheral sympathetic stimulation. Just as with the other drugs, DOM increased plasma free fatty acids, decreased phosphorus and creatinine clearance, decreased circulating eosinophils and had little effect on catecholamine excretion. Performance of psychometric tests was impaired. Chlorpromazine treatment concurrently was found to attenuate the reaction. Tolerance rapidly developed when the drug was used chronically by patients.
This is a preview of subscription content, log in via an institution to check access.
References
Alles, G. A.: Some relations between chemical structures and physiological action of mescaline and related compounds. Neuropharmacology. Josiah Macy, Jr., Foundation, Madison 1959.
Clyde, D. J.: Manual for the clyde mood scale. 15 pp. Univ. of Miami, Coral Gables, Fla., 1963.
Crout, J. R., and D. Abraham: Determination of 3-methoxy-4-hydroxymandelic acid in urine. Clin. chim. Acta 7, 285 (1962).
Hollister, L. E., and A. M. Hartman: Mescaline, lysergic acid diethylamide and psilocybin: Comparison of clinical syndromes, effects on color perception and biochemical measures. Comprehens. Psychiat. 3, 235 (1962).
— and B. M. Sjoberg, Jr.: Clinical syndromes and biochemical alterations following mescaline, lysergic acid diethylamide, psilocybin and a combination of the three psychotomimetric drugs. Comprehens. Psychiat. 5, 170 (1964).
— and A. J. Friedhoff: Effects of 3,4-dimethoxy-phenlyethylamine in man. Nature (Lond.) 210, 1377 (1966).
Moran, L. J.: Repetitive psychometric measures. Hogg Foundation for Mental Health, Austin, Texas 1959.
Shulgin, A. T.: 3-methoxy-4,5-methylenedioxy amphetamine, a new psychotomimetic agent. Nature (Lond.) 210, 1120 (1964).
Smythies, J. R., R. J. Bradley, V. S. Johnston, F. Benington, R. D. Morin, and L. C. Clark, Jr.: Structure-ac tivity relationship studies on mescaline III. The influence of the methoxy groups. Psychopharmacologia (Berl.) 10, 379 (1967).
Snyder, S. H., L. Faillace, and L. Hollister: 2,5-dimethoxy-4-methyl-amphetamine (STP): A new hallucinogenic drug. Science 158, 669 (1967).
Trout, D. L., R. H. Estes, Jr., and S. J. Friedberg: Titration of free fatty acids in plasma. A study of current methods and a new modification. J. Lipid Res. 1, 199 (1960).
Author information
Authors and Affiliations
Additional information
Supported in part by Grant MH 03030, National Institute of Mental Health.
Rights and permissions
About this article
Cite this article
Hollister, L.E., Macnicol, M.F. & Gillespie, H.K. An hallucinogenic amphetamine analog (DOM) in man. Psychopharmacologia 14, 62–73 (1969). https://doi.org/10.1007/BF00401535
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00401535